Korea Health Industry Development Institute, China pharmaceutical bio investment briefing held

The Korea Health Industry Development Institute (KHIDI) announced on the 31st that it held the `China Pharmaceutical Bio Investment Briefing (IR)` on the 20th, where domestic pharmaceutical companies introduced their technologies to Chinese investors. This event was jointly held with the Shanghai office of NH Investment & Securities. 10 domestic companies made IR presentations.

KISA is operating 4 branches (USA, China, UAE, Kazakhstan), and this event will be held at the Chinese branch (branch manager Yun Joo-han) for Korean companies to advance into the Chinese market in the future, `operating an entry support platform`, `online business briefing`, ` It was planned as part of the `Global Partnership Support Project`.

At the investment briefing session, three Chinese investors, Aoyuan Beauty, Orix, and Qilu Pharma, will participate. On April 28, these three investment companies held a briefing session to introduce their companies and investment strategies to 30 domestic companies.

Aoyuan Beauty is a company that handles plastic beauty, cosmetics, and medical devices for plastic surgery in southeastern China. He also has many investment experiences with Korean companies.

ORIX is a Japanese general investment company with its Asia-Pacific headquarters located in Shanghai.

Qilu Pharmaceutical is a top 10 pharmaceutical company in China and the 25th largest pharmaceutical company in the world, with strength in the field of anticancer drugs. In terms of sales, it also ranked second in the Chinese market last year. Currently, it is conducting collaborations such as joint research and licensing with world-class pharmaceutical companies, and is actively investing in advanced biotechnology.

In this investment briefing session, 10 domestic pharmaceutical bio and cosmetics companies participated and introduced their excellent products and technologies to investors.

Chinese investors plan to review the market entry of participating companies and the possibility of business cooperation, conduct discussions step by step, and develop overall cooperative projects related to market entry through partnerships with the finally selected companies.

“There are many companies with excellent products and technologies in Korea, but there are many companies that have difficulties in overseas expansion due to funding and partnership issues,” said Kim Yong-woo, head of the Pharmaceutical Bio Industry Group at the Korea Development Institute. I hope it will serve as an opportunity to lead open innovation,” he explained.

Yoon Joo-han, head of the Chinese branch of the Korea Development Institute, said, “China is Asia’s largest market for exports of pharmaceuticals, medical devices and cosmetics from Korea. I hope it will serve as an opportunity to build a new cooperative chain in the field of biohealth.”

This event was the first investment briefing held by KHIDI with foreign investors, and many participating companies responded positively.

Regarding the investment briefing session, Kim Myeong-rip, CEO of Bilix, said, “While it takes considerable funds, effort, and time to directly attract overseas investment and technology transfer that Bilix needed, the Korea Development Institute directly stepped forward to find excellent overseas investors and promote partnering. Giving an opportunity is a huge help,” he said. “I hope that there will be more events like this in the future, leading to actual success stories.”

An official from the KHIDI said, “We plan to hold more investment companies in the second half of the year, and we plan to introduce excellent Korean companies to investors not only in China but also in various countries.”